143 related articles for article (PubMed ID: 36831376)
1. Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Tuninetti V; Ghisoni E; Pignata S; Picardo E; Raspagliesi F; Andreetta C; Maldi E; Artioli G; Mammoliti S; Zanchi L; Sikokis A; Biglia N; Parisi A; Mandato VD; Carella C; Cormio G; Marinaccio M; Puppo A; Paolini B; Borsotti L; Scotto G; Turinetto M; Sangiolo D; Di Maio M; Valabrega G
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831376
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.
Romeo M; Gil-Martín M; Gaba L; Teruel I; Taus Á; Fina C; Masvidal M; Murata P; Fernández-Plana J; Martínez A; Pérez C; García Y; Rodriguez V; Cros S; Parera M; Zanui M; Catot S; Pardo B; Plaja A; Esteve A; Barretina-Ginesta MP
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139574
[TBL] [Abstract][Full Text] [Related]
3. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
4. What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China.
Zhang D; Li S; Zhang X; Peng J; Zhang S
Front Oncol; 2022; 12():955124. PubMed ID: 36059631
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer.
Nicoletto MO; Baldoni A; Cavallin F; Grego A; Falci C; Nardin M; Mammano E; Lai E; Torri V
Ther Adv Med Oncol; 2023; 15():17588359231173181. PubMed ID: 37360767
[TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
[TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Lee EK; Matulonis UA
Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
[TBL] [Abstract][Full Text] [Related]
8. Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
Gadducci A; Cosio S; Landoni F; Lissoni AA; Zola P; Laudani ME; Ardizzoia A; Gambino A; Sartori E
Anticancer Res; 2022 Apr; 42(4):2017-2022. PubMed ID: 35347023
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250
[TBL] [Abstract][Full Text] [Related]
10. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
Wang H; Wu M; Liu H; Zhou H; Zhao Y; Geng Y; Jiang B; Zhang K; Zhang B; Han Z; Du X
Front Oncol; 2021; 11():785102. PubMed ID: 34900739
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
Marchetti C; Ataseven B; Perrone AM; Cassani C; Fruscio R; Sassu CM; Apostol AI; Harter P; De Iaco P; Camnasio CA; Moubarak M; Giannarelli D; Scambia G; Fagotti A
Gynecol Oncol; 2024 May; 187():170-177. PubMed ID: 38788514
[TBL] [Abstract][Full Text] [Related]
13. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
14. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
Perez JM; Twigg CAI; Guan W; Thomas SN
J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
[TBL] [Abstract][Full Text] [Related]
15. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
Rose PG; Yao M; Chambers LM; Mahdi H; DeBernardo R; Michener CM; AlHilli M; Ricci S; Vargas R
Anticancer Drugs; 2021 Nov; 32(10):1086-1092. PubMed ID: 34520432
[TBL] [Abstract][Full Text] [Related]
17. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
18. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Park J; Lim MC; Lee JK; Jeong DH; Kim SI; Choi MC; Kim BG; Lee JY
J Gynecol Oncol; 2022 Mar; 33(2):e12. PubMed ID: 34910393
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer.
Gao L; Chen R; Li T; Li L; Zheng Q
Front Pharmacol; 2021; 12():771836. PubMed ID: 34819864
[No Abstract] [Full Text] [Related]
20. Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
Yubero A; Barquín A; Estévez P; Pajares B; Sánchez L; Reche P; Alarcón J; Calzas J; Gaba L; Fuentes J; Santaballa A; Salvador C; Manso L; Herrero A; Taus Á; Márquez R; Madani J; Merino M; Marquina G; Casado V; Constenla M; Gutiérrez M; Dosil A; González-Martín A
BMC Cancer; 2022 Nov; 22(1):1150. PubMed ID: 36348385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
